ڿ Ƽ õ Դϴ.
鿪 ̻ ڱ ıϴ ༺ ̶ մϴ. ġϱ ϳ gene therapy ġԴϴ. ڿտ Ƽ ϰ ִ Դϴ. ̴ , 鿪 ġԴϴ.
ڰ鿪̻ ġ ã 迡 ڱ ʿϿϴ. ġῡ Ź ã ž Ͽ ӻ ǰ ϱ 15 20 ð ɸ, ּʾ ڱ ҿ˴ϴ.
Ʒ ġῡ Դϴ. ġḦ ߺ۰ и, , 뷮Ŀ ̸ Ϳ Ͽ ϴ. Ƽ ڿ ڴ 400( ۴ 50% ) ̾ϴ. ܰ踦 ģ 6.9% پϴ. ܰ ڱ ǰ ð ҿ ƹ ϴ.
̰ Ͼ ߸ ༺ ̴. 츮 缱 Ұ 55 ̻ 80%, 70 ̻ α ༺ Ÿ 1/4 ӻ Ÿ ǥ ༺ ȯ̴. ȭ ȸ ༺ȯ ġ ϰ ִ. ϰ ִ , 2000 ġμ ҿ Ը 1,000뿡 ̸ ȸ õ ġ Ѵ. ༺ ־ ̳ ٺ ġ ߵ ʰ ִ. ܿ ȭ ġ ȣ (˷л, ۷ڻ, ܵƾ) ߵǾ ̵ ȣμ ȣ, ݿȭ, , ϳ, ȿ Ȯ ʾҰ ƹ .
[༺ ġ]
|
|
|
ġ |
|
, ƽǸ |
̵ |
ֻ (ֻ), ۿ | |
̵ |
ۿ | |
ȣ (˷л, ۷ڻ,ܵƾ) |
ȣ, ݿȭ, , | |
|
, , κ ġȯ, ġȯ |
ô, , Ȱ, ̼õ, 밨, , κ, ΰ |
ġ |
µ ܰ |
üܿ ̽ϰų ڵԿ |
ڼؿ ش ǥ Ѵ. ECM ı ϱ MMP Ȱ TIMP Ȱ, recombinant human IL-1 antagonist (ILRA) ؼ IL-1 receptor , , COX-2 õǰ ִ. ɼ ο ǥ ڰ ν ȴ.
ֱ õǰ ִ üܿ Ȥ ̺ȭ ȭ ̽ϰų ڵԿ ϴ cell therapy, tissue engineering, gene therapy õǰ ִ. ġ chondroprogenitor ٷ ǰ ȹϴ ʼ̹Ƿ ݵǴ Żȭ ȿ ȭ ʿϴ. Ϻ ڸ ̿ ġ õǰ ̽ı ̽ĵ Ȱ ؼ õܰ迡 Ұϴ. ̷ غ ȴ.
[Cell therapy tissue engineering ]
ջ Ű ȭ Ľ ڰ ̽ϴ cell therapy ̿ȴ. ȭ üܿ ϸ Ư ռϰ, ӻ 迡 80% ȯڿ ȿ Ÿ . ü ̿Ͽ üܿ ϰ ̸ ̽ϴ δ ּ õǰ ִ. ̽ĵ long-term fate Ը ʾ ̷ ʿ Ѵ. 뷮 ݵǴ Żȭ ȿ Ȥ Żȭ ȭ ذ Ѵ. ̷ ذϱ ٸ μ periosteum bone marrowκ stem cell Ȥ chondroprogenitor cel иؼ ̿ϴ ̴. chondroprogenitor ջ ϰų üܿ ȭ ϴ μ δ ɼ ٹ̴. Chondroprogenitor ϴ ̽ 4 ȭ ǰ 1 Ŀ cartilage ǥ ĥ β ̷ ʾ Ư ̽ progenitor , Ѵü Ȥ delivery vehicle о߿ ʿ ִ.
[Gene therapy ]
Gene therapy ջ ٸ ȴ. gene therapy ؼ , delivery, ذǾѴ. õǰ ִ ڷμ IL-1 receptor antagonist (IL-1Ra), soluble TNF receptor (sTNFR), transforming growth factor-beta (TGF-) ִ. retrovirus ̿ sTNFR TGF- Ƽ ҽŰ . Gene therapy ־ ȿ ڸ ϴ°ϴ delivery ý ſ ߿ μ retrovirus, adenovirus, adeno-associated virus õǰ ִ. Ե ڰ ǴĴ ͵ ٸ gene therapy θ ϴ μ Ͻ Ǿ ʿ ȴ. ־ cell therapy, tissue enginnering, gene therapy ı Ӹ ƴ϶ ջ ִ .
ڻ, , 鿪 Ϲ ϱ κ , ϰ ִ ġḦ ġ ɼ , ü ϱ 庮 ۿ ġ ȿ Ȯ Ҵٴ Դϴ.
Ƽ ѱ ڵ ˸ ڶϴ. 忡 ü ø ״θ 鿩 ˴ϴ. Ī ũ ؾ Դϴ.
Դϴ.
Ȯ ǥڸ Ǿٴ ϴٰ ˴ϴ.
ݸ鿡 ̷ ҽ ?
̱..
մϴ.
ڿ ؼ Ƽ Դϴ.
ø ϸ ڿȭ Ƽ
2002 5 6 6õ (2%)
2003 ߰ڷ 25 6.87% Ȯ, ڱݾ 18 49鸸 Ǿ,
2004 6 սó 5 28鸸 Ǿ ΰ Ǿϴ.
ٴ ӵ ں پϴ. ߰ ڰ ʿ ̰,
ؾұ?